$6.34
0.132.09%
At close: Aug 6, 5:00 PM EST
$6.30
0.091.45%
Pre-Market: 6:02 AM EST
Iovance Biotherapeutics Inc
IOVANASDAQ
Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open
Conference Call: The most recent conference call started at 8:30 AM, 4 days agoClick to view the webcast
Iovance Biotherapeutics Earnings & Forecasts
Iovance Biotherapeutics (IOVA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Iovance Biotherapeutics Guidance
Iovance Biotherapeutics (IOVA) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided revenue in the range of $350M - $370M for the period.
Compared to prior guidance, Iovance Biotherapeutics maintained its revenue forecast from a prior range of $350M - $370M.
Iovance Biotherapeutics has issued 12 guidance updates between August 8, 2024 and August 6, 2026. During this period, the company raised its outlook 3 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.14 | $-0.16 | $-0.19 | $-0.27 |
| Actual | $-0.11 | $-0.19 | $-0.18 | $-0.25 |
| Surprise | +21.4% | -18.8% | +5.26% | +7.41% |
| Revenue | ||||
| Estimate | $87.6M | $76.0M | $78.6M | $71.8M |
| Actual | $99.3M | $71.4M | $86.8M | $67.5M |
| Surprise | +13.4% | -5.96% | +10.3% | -6.08% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.10 | $-0.11 | $-0.10 | $-0.11 |
| Revenue | ||||
| Consensus | $105.7M | $117.5M | — | — |
